TITLE

Transparency in PBMs may be solution or new set of problems

AUTHOR(S)
Maas, Angela
PUB. DATE
December 2004
SOURCE
Employee Benefit News;Dec2004, Vol. 18 Issue 15, p42
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the need for pharmacy benefit managers (PBM) in the U.S. Information on PBM disclosure pricing in the country, Discussion on financial agreements being made by PBM with the country's pharmaceutical industry; Details of transparent pricing arrangements being offered by Watson's Pharmaceutical Strategies Group in the country. INSETS: Judging transparency;Untitled.
ACCESSION #
15247604

 

Related Articles

  • The Drug Price Battle Continues. Taylor, Humphrey // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p20 

    Reports on the victory of the pharmaceutical industry with the Medicare drug benefit bill in the U.S. Administration of the bill by private sector insurance plans; Reduction of the out-of-pocket drug costs of Medicare beneficiaries, increase drug-regime compliance and increase product sales;...

  • Drug industry trends help employers. Bennett, Catherine D. // National Underwriter / Life & Health Financial Services;2/6/95, Vol. 99 Issue 6, pS3 

    Reports that the trend toward consolidation and vertical integration in the pharmaceutical industry has spurred competition and generated favorable terms for benefits buyers. Ideal opportunity for employers to develop prescription drug programs; Setting up of separate reimbursement programs;...

  • A brief history of third party. O'Malley, Kevin Shea // Drug Topics;5/17/99, Vol. 143 Issue 9, p15 

    Comments on third party plans for pharmaceutical services in the United States. Advantages of electronic claim submission; Impact of third-party plans to the pharmaceutical industry; Information on switching practice in the industry.

  • Medicare Rx benefit is no magic PR bullet. Arnold, Matthew // Medical Marketing & Media;Aug2003, Vol. 38 Issue 8, p118 

    Focuses on proposed prescription drug benefit for Medicare recipients in the United States. Structural solutions needed; Benefits of drug companies.

  • 2. PHARMACEUTICAL INDUSTRY IN AUSTRALIA: 2.4. ACCESSIBILITY: KEY FACTORS.  // Pharmaceutical Industry in Australia: A Strategic Reference, 200;2003, p14 

    The article discusses major factors for drug accessibility in Australia in the 1990s. More than 80 percent of prescription drugs are sold through the Pharmaceutical Benefits Scheme. The Therapeutic Reference Pricing is used to determine government subsidy to drugs that treat high blood pressure,...

  • Who earns what where? Ukens, Carol // Drug Topics;9/4/2000, Vol. 144 Issue 17, p45 

    Presents several news briefs related to technological innovations in pharmacy as of September 2000. Information on the web page www.salary.com which provides data on salary comparisons in the pharmaceutical industry; Details on the integration of prescription records of military personnel by...

  • Pharmaceutical affordability and value.  // Pharmaceutical Representative;Mar2005, Vol. 35 Issue 3, p36 

    Part III. Discusses the issues behind drug affordability and the challenge of demonstrating the value of pharmaceuticals. Realization that the expanding use of medications, not rising drug prices, accounts for most of the increase in pharmaceutical expenditures; Major prescription drug insurance...

  • PBMs to the rescue? Fong, Tony // Modern Healthcare;11/28/2005, Vol. 35 Issue 48, p26 

    The article focuses on the role to be played by pharmacy benefit managers (PBM) in the Medicare drug benefit in the U.S. Management of drug benefit in order to be cost-effective is the mission of PBM. Government studies claim that PBM have prevented further increase in medicine cost. Some PBM...

  • Drug Pricing and Value in Oncology. Danzon, Patricia M.; Taylor, Erin // Oncologist;Mar2010 Supplement, Vol. 15, p24 

    This paper examines the issue of prices, relative to value, for cancer drugs. The analysis focuses on the effects on manufacturer pricing incentives of insurance coverage, specifically, the effectiveness of patient cost sharing, incentives created by reimbursement rules for physician-dispensed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics